Current Issues in Public Health Genomics

Muin J. Khoury MD, PhD
Office of Genomics and Disease Prevention, CDC





Overview

Public Health in the Genomics Era


 Examples of CDC Public Health Genomics Building Block Initiatives

Near Term Directions





Welcome to the Genomics Era!





Nature 2005

ARTICLES

A haplotype map of the human genome

The International HapMap Consortium*

Inherited genetic variation has a critical but as yet largely uncharacterized role in human disease. Here we report a public database of common variation in the human genome: more than one million single nucleotide polymorphisms (SNPs) for which accurate and complete genotypes have been obtained in 269 DNA samples from four populations, including ten 500-kilobase regions in which essentially all information about common DNA variation has been extracted. These data document the generality of recombination hotspots, a block-like structure of linkage disequilibrium and low haplotype diversity, leading to substantial correlations of SNPs with many of their neighbours. We show how the HapMap resource can guide the design and analysis of genetic association studies, shed light on structural variation and recombination, and identify loci that may have been subject to natural selection during human evolution.





"The SNPs are down: genotyping for the rest of us"

"Human genotyping has never been hotter, and a sophisticated set of array-based tools now simplifies the process dramatically, facilitating everything from small basic research studies to complex genetic epidemiology."

A. Dove. Nat Methods 2005;2, 989 - 994






"Gene Increases Diabetes Risk, Scientists Find" (New York Times, January 16, 2005)

"Scientists have discovered a variant gene that leads to a sizeable extra risk of Type 2 Diabetes and is carried by more than a third of Americans...An immediate practical consequence of the discovery would be to develop a diagnostic test to identify people who carry the variant gene. If people knew of their extra risk, they would have an incentive to stay thin and exercise."

Grant SFA et al. Nat Genet Jan 2006








other genotypes, yielding a risk ratio of 4.2 (95% confidence

interval [CI], 2.3-7.8; follow-up time, age, and sex were not

and routines embedded in electronic medical records,

and direct mailings to patients [2]. Greater adoption of

"Genetic Testing for Sale"






09/11/03—Reinforcing its position as a pharmacogenomics pioneer, diagnostic giant Roche launched in June a P450 chip measuring DNA markers for predicting patient responses to many common drugs.

The AmpliChip CYP450 test is based on the Affymetrix GeneChip DNA analysis platform. The chip detects variations in DNA that are known to affect genes controlling the body's mechanisms for processing drugs, and it is the first chip using Affymetrix technology that meets federal standards for clinical use. The test can be run only in reference laboratories, which must meet specific certification standards. In the future, though, it could become easier to use in a variety of settings.










What is "Public Health Genomics"? (Institute of Medicine, 2005)


 "An emerging field that assesses the impact of genes and their interaction with behavior, diet and the environment on the population's health"







The Public Health Genomics Enterprise







Public Health Genomics at CDC

Examples of Building Block Initiatives

- Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
- Family History Public Health Initiative
- National Profile of Genetic Variation
- Integrating Genomics into Public Health Investigations and Preparedness
- Public Health Genomics Response Capacity





Evaluation of Genomic Applications in Practice and Prevention (EGAPP)

Benefit: Build the Evidence Base

- Independent panel to evaluate genetic tests and other genomic applications
- Provide evidence base for practitioners and protect public from harm
- CDC accepts key leadership role recommended by many groups
- Extends CDC efforts in newborn screening and







Family History Public Health Initiative

Benefit: Tools for Prevention

- Family history captures shared genes, behaviors, and environment
- Use to target screening, prevention
- CDC tool (6 diseases) & validation study in collaboration with CDC, NIH, academia
- Partnership with Surgeon General







National Profile of Genetic Variation

Benefit: Population Data for Health Impact

- NHANES: Representative sample of U.S. population with rich clinical, laboratory and exposure data
- Needed for estimating numbers of people at risk and who could benefit from interventions

- CDC working group projects:
 - •Phase I: 100-200 variants
 - •Phase II: 300,000-500,000 variants






Genomics in Public Health Investigations

Benefit: Prevent and Control Disease in Communities

- Pathogen genomics a key public health tool
- Human genomics: susceptibility, vaccine and drug response, adverse effects
- Identify environmental factors for intervention








Public Health Genomics Response Capacity

Benefit: Prepare public health capacity & workforce

- Centers for excellence in genomics & public health
- Integrating genomics into state programs
- Public health genomics workforce competencies
- Reports, website, online courses, weekly update





Public Health Genomics: a Vision for the Future

2016

CDC attains more health impact goals

Healthy people in every life stage

Healthy people in healthy places

Preparedness for health threats

Global health

2006



Public Health Genomics: a Vision for the Future

2016

CDC attains more health impact goals

Healthy people in every life stage

Healthy people in healthy places

Preparedness for health threats

Global health

2006

Understand health effects of gene-environment interaction via public health investigations

Determine prevalence of gene variants in the US and within communities

Develop and make family history tools available for prevention

Evaluate genetic tests to build evidence base for practice





Public Health Genomics: a Vision for the Future

2016

CDC attains more health impact goals

Public health genomics laboratory capacity

Trained public health workforce

Understand health effects of gene-environment interaction via public health investigations

Public health informatics genomics capacity

Determine prevalence of gene variants in the US and within communities

2006

Develop and make family history tools available for prevention

Evaluate genetic tests to build evidence base for practice





Near Term Directions in Public Health Genomics at CDC

- Enhancing networking and collaborations
- Developing CDC goals oriented initiatives

- Making seed funding available
- Emphasizing career development



